Evidence map›Paper›PMID 29971621›Full record

ArticleInternational journal of clinical oncology2018

Present clinical practices of stereotactic irradiation for metastatic brain tumors in Japan: results of questionnaire survey of the Japanese Radiation Oncology Study Group (JROSG) working subgroup for neurological tumors.

Ken Harada, Hiroshi Igaki, Eisuke Abe, Takuro Ariga, Nobuyuki Hayashi, Ayae Kanemoto, Takafumi Komiyama, Yasuo Matsumoto, Toshimichi Nakano, Rikiya Onimaru and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Ken HaradaDepartment of Radiation Oncology, School of Medicine, Tokai University, Kanagawa, Japan.
Hiroshi IgakiDepartment of Radiation Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. hirigaki@ncc.go.jp.ORCID http://orcid.org/0000-0001-7817-624X
Eisuke AbeDepartment of Radiology and Radiation Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Takuro ArigaDepartment of Radiology, Graduate School of Medical Science, University of the Ryukyus, Nakagami, Japan.
Nobuyuki HayashiDepartment of Radiotherapy, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.
Ayae KanemotoDepartment of Radiation Oncology, Niigata Cancer Center Hospital, Niigata, Japan.
Takafumi KomiyamaDepartment of Radiology, University of Yamanashi, Yamanashi, Japan.
Yasuo MatsumotoDepartment of Radiation Oncology, Niigata Cancer Center Hospital, Niigata, Japan.
Toshimichi NakanoDepartment of Radiology and Radiation Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Rikiya OnimaruDepartment of Radiation Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Hirotake SaitoDepartment of Radiology and Radiation Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Minako SumiDepartment of Radiation Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Masao TagoDepartment of Radiology, Teikyo University Mizonokuchi Hospital, Kawasaki, Japan.
Kensuke TanakaDepartment of Radiology and Radiation Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Katsuya MaebayashiDivision of Radiation Therapy, Nippon Medical School Hospital, Tokyo, Japan.
Hidefumi AoyamaDepartment of Radiology and Radiation Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Japanese Radiation Oncology Study Group (JROSG) Working Subgroup for Neurological Tumors

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo determine the current practice of stereotactic irradiation (STI) for brain metastases in Japan by a questionnaire survey.

methodsA questionnaire was distributed to 313 institutions performing STI with one of the following machines: Gamma Knife (GK), CyberKnife (CK), Novalis (Nov), or other linear accelerator (LINAC)-based systems (OLS). The participation was voluntary.

resultsThere were 163 responding institutions. The total number of STI treatments between April 2013 and March 2014 was 10,684. Stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (SRT) were performed in 8624 (80.7%) and 2060 (19.3%) cases, respectively. Whole-brain radiation therapy (WBRT) was performed for a total of 3515 cases. For a case model of a 1.5-cm solitary brain metastasis in a non-eloquent area, the most common GTV-PTV margin was 2 mm (22 of 114 institutions), and an institutional standard fraction was 1 (75 of 114 institutions). The doses for the model case also varied from 13.0 to 26.0 Gy (Median 20 Gy) when converted to SRS (α/β = 10). A prescription point was at the PTV margin the most. The median dose constraints which were converted to SRS (α/β = 3) to organs at risk were 12.2, 12.7, and 13.7 Gy for optic nerves, cavernous sinus, and brainstem, respectively.

conclusionsSTI for brain metastases in current practice varied significantly among institutions. These different strategies relied mostly on the type of treatment machine used. It is thus necessary to establish a common guideline to express dose prescriptions and plan qualities for different STI machines.

Indexed as

Brain NeoplasmsHumansJapanPractice Patterns, Physicians'Radiation OncologyRadiosurgerySurveys and QuestionnairesBrain metastasesStereotactic irradiationSurvey in Japan

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.